DelveInsight’s, “RIPK1 inhibitor Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in RIPK1 inhibitor pipeline landscape. It covers the RIPK1 Inhibitor pipeline RIPK1 inhibitor drug profiles, including RIPK1 inhibitor clinical and nonclinical stage products. It also covers the RIPK1 inhibitor therapeutics assessment by product type, stage, RIPK1 inhibitor route of administration, and RIPK1 inhibitor molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ RIPK1 Inhibitor Pipeline Outlook Report
Key Takeaways from the RIPK1 Inhibitor Pipeline Report
- DelveInsight’s RIPK1 Inhibitor pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for RIPK1 Inhibitor treatment.
- The leading RIPK1 Inhibitor Companies such as Sanofi, Sironax, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Rigel Pharmaceuticals, Voronoi, Boston Pharmaceuticals, Sironax, Sironax, Nuevolution and others.
- Promising RIPK1 Inhibitor Pipeline Therapies such as SAR443122, GFH312, R552, and others.
Learn how leading RIPK1 Inhibitor Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ RIPK1 Inhibitor Clinical Trials Assessment
RIPK1 Inhibitor Emerging Drugs Profile
- SAR443122: Sanofi
SAR443122 (DNL758) is a small molecule inhibitor of a protein known as RIPK1 (receptor-interacting serine/threonine-protein kinase 1), which is involved in the tumor necrosis factor (TNF) receptor pathway that is implicated in inflammation, immunity, and cell death. RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. Sanofi has successfully completed the Phase I study with peripherally-restricted RIPK1 inhibitor DNL758(c) to treat SARS-CoV-2 viral infection and conducting Phase II clinical trial to treat Cutaneous Lupus Erythematosus. Furthermore, Sanofi plans to initiate a Phase II trial of SAR443122 in patients with ulcerative colitis
- GFH312: GenFleet Therapeutics
GFH312 is a small molecule inhibitor of receptor-interacting serine/threonine protein-1(RIP1) kinase, a key regulator of the TNF-α downstream. GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage. Preclinical data of GFH312 have demonstrated its effects in suppressing inflammation (peripheral and neuronal), reducing pathological as well as behavioral deficits, and improving survival in animal models with acute systemic inflammation resulting from multiple tissue injury. GFH312 effectively inhibit the activity of RIPK1, and the Phase I trial will explore its safe dose range and tolerability in healthy subjects providing basis for further clinical development.
- R552: Rigel Pharmaceuticals
R552, the drug is supposed to block an enzyme that plays a role in a wide range of cellular processes, including inflammation and cell death. Eli Lilly and Rigel Pharmaceuticals have collaborated to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 or RIPK1 inhibitor, for the potential treatment of immunological and neurodegenerative diseases. Rigel’s lead RIPK1 inhibitor, R552, has completed Phase I clinical trials and the planning to begin Phase II clinical trials is underway as part of the collaboration.
The RIPK1 Inhibitor Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of RIPK1 Inhibitor with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RIPK1 Inhibitor Treatment.
- RIPK1 Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- RIPK1 Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RIPK1 Inhibitor market.
From early-stage research to late-phase RIPK1 Inhibitor Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ RIPK1 Inhibitor Treatment Drugs
RIPK1 Inhibitor Companies
Sanofi, Sironax, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Rigel Pharmaceuticals, Voronoi, Boston Pharmaceuticals, Sironax, Sironax, Nuevolution and others.
RIPK1 inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
RIPK1 Inhibitor Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Stay updated with the latest RIPK1 Inhibitor Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ RIPK1 Inhibitor Market Drivers and Barriers, and Future Perspectives
Scope of the RIPK1 Inhibitor Pipeline Report
- Coverage- Global
- RIPK1 Inhibitor Companies- Sanofi, Sironax, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Rigel Pharmaceuticals, Voronoi, Boston Pharmaceuticals, Sironax, Sironax, Nuevolution and others.
- RIPK1 Inhibitor Pipeline Therapies- SAR443122, GFH312, R552, and others.
- RIPK1 Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- RIPK1 Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest RIPK1 Inhibitor Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ RIPK1 Inhibitor Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- RIPK1 inhibitors: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Mid Stage Products (Phase II)
- SAR443122: Sanofi
- Early Stage Products (Phase I)
- GFH312: GenFleet Therapeutics
- Preclinical Stage Products
- BOS-421: Boston Pharmaceuticals
- Inactive Products
- RIPK1 inhibitors Key Companies
- RIPK1 inhibitors Key Products
- RIPK1 inhibitors- Unmet Needs
- RIPK1 inhibitors- Market Drivers and Barriers
- RIPK1 inhibitors- Future Perspectives and Conclusion
- RIPK1 inhibitors Analyst Views
- RIPK1 inhibitors Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ripk1-inhibitor-pipeline-insight